Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumor, Adult: early-phase trial registry
48 of 73 indexed Solid Tumor, Adult trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #188 of 28,707 conditions by registered trial count.
73 US clinical trials · 48 currently recruiting · #188 of 28,707 conditions by registered trial count
Solid Tumor, Adult: 73 US clinical trials tracked, 48 recruiting.
Solid Tumor, Adult is the subject of 73 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 61 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition solid-tumor-adult
OPEN 48 | RECR 66% | LATE 0 | EARLY 61 | RANK #188 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Hematopoietic and Lymphoid System Neoplasm (66% recruiting · 32 trials)
Solid Tumor, Adult lists 48 open slots (66% of 73 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumor, Adult on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumor, Adult is recruiting above its size-band peers.
48 of 73 indexed trials (65.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumor, Adult trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 7 of 73 trials (9.6%). 60 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumor, Adult enrolment sits around 115 participants.
Median target enrolment is 115 among the 73 trials that report a genuine target (sentinel values excluded). 32 of those (43.8%) plan for fewer than 100 participants.
-
Solid Tumor, Adult research is mostly interventional.
69 interventional and 4 observational studies make up this index (94.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
73 total, page 1 of 2
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
BioCytics
NCT00571389
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics
NCT05216432
Personalized Models for Cancer Research
New York Stem Cell Foundation Research Institute
NCT06350539
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06051695
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Frontier Medicines Corporation
NCT06244771
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06625775
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Immatics US
NCT03686124
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT05669430
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
DualityBio
NCT06554795
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals
NCT06265727
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics
NCT04665206
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem
NCT07020221
Psychotherapy Intervention for Latinos With Adv Cancer
Memorial Sloan Kettering Cancer Center
NCT04537936
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Krystal Biotech
NCT06228326
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
Memorial Sloan Kettering Cancer Center
NCT04942717
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Nested Therapeutics
NCT06326411
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04165772
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Linnaeus Therapeutics
NCT04130516
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
BioInvent International AB
NCT04219254
Psychotherapy Intervention for Latinos With Advanced Cancer
Memorial Sloan Kettering Cancer Center
NCT04015609
First In Human Study of CX-2051 in Advanced Solid Tumors
CytomX Therapeutics
NCT06265688
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT06586957
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx
NCT04673942
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
NCT05856981
DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer
Memorial Sloan Kettering Cancer Center
NCT07225088
First In Human Study of CX-801 in Advanced Solid Tumors
CytomX Therapeutics
NCT06462794
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
NCT06218914
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Tyra Biosciences
NCT06915753
Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer
Good Samaritan Hospital Medical Center, New York
NCT05947695
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences
NCT06507306
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
Trethera
NCT05055609
64Cu-GRIP B in Patients With Advanced Malignancies
Rahul Aggarwal
NCT05888532
Intravital Microscopy in Human Solid Tumors
Mayo Clinic
NCT03823144
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
NCT03919292
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Crossignal Therapeutics
NCT06598007
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Shenzhen Ionova Life Sciences Co.
NCT04443088
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
Medical University of South Carolina
NCT05036226
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention
University of California, Davis
NCT06436157
A Study of VET3-TGI in Patients With Solid Tumors
KaliVir Immunotherapeutics
NCT06444815
Advanced or Recurrent Solid Tumors Treated With SHetA2
University of Oklahoma
NCT04928508
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings
NCT04196257
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
University of Texas Southwestern Medical Center
NCT07139990
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03465592
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics
NCT06398418
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Effector Therapeutics
NCT04092673
Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.
University of Colorado, Denver
NCT04739696
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
NCT04913285
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumor, Adult records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumor, Adult trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumor, Adult page
73 registered trials, 48 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 48 Solid Tumor, Adult trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Solid Tumor, Adult trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumor, Adult condition card totals 73 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.